Form 8-K Annual Meeting Voting Results 2014


 
 
 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

__________________

FORM 8-K
__________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 24, 2014


Lexicon Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)


Delaware
000-30111
76-0474169
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)


8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of principal executive
offices and Zip Code)


(281) 863-3000
(Registrant’s telephone number,
including area code)


Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
o
Pre-commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
 
 
 
 
 





Item 5.07
Submission of Matters to a Vote of Security Holders

Our annual meeting of stockholders was held on April 24, 2014 to consider and vote on the following proposals. The voting results with respect to each matter are set forth below:
(1)
Election of Class II Directors:
 
 
 
 
Name of Director
For
Withheld
Broker 
Non-Votes
 
Samuel L. Barker, Ph.D.
439,069,672
1,814,556
40,863,921
 
Christopher J. Sobecki
425,017,763
15,866,465
40,863,921
 
Judith L. Swain, M.D.
438,346,715
2,537,513
40,863,921

 
 
For
Against
Abstain
Broker Non-Votes
(2)
Advisory vote to approve the compensation paid to our named executive officers
436,314,991
2,636,328
1,932,909
40,863,921

 
 
For
Against
Abstain
Broker Non-Votes
(3)
Ratification and approval of the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2014
480,710,744
673,135
364,270
0








Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Lexicon Pharmaceuticals, Inc.
 
 
 
 
 
 
Date: April 24, 2014
By:
/s/ Brian T. Crum
 
 
Brian T. Crum
 
 
Vice President and General Counsel